The transforming growth factor b (TGFb) signalling pathway plays a central role during embryonic development and in adult tissue homeostasis. It regulates gene transcription through a signalling cascade from cell surface receptors to intracellular SMAD transcription factors and their nuclear cofactors. The extent, duration and potency of signalling in response to TGFb cytokines are intricately regulated by complex biochemical processes. The corruption of these regulatory processes results in aberrant TGFb signalling and leads to numerous human diseases, including cancer. Reversible ubiquitylation of pathway components is a key regulatory process that plays a critical role in ensuring a balanced response to TGFb signals. Many studies have investigated the mechanisms by which various E3 ubiquitin ligases regulate the turnover and activity of TGFb pathway components by ubiquitylation. Moreover, recent studies have shed new light into their regulation by deubiquitylating enzymes. In this report, we provide an overview of current understanding of the regulation of TGFb signalling by E3 ubiquitin ligases and deubiquitylases.
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The transforming growth factor b signalling pathway
The transforming growth factor b (TGFb) family of cytokines control a plethora of cellular processes, including proliferation, differentiation, extra-cellular matrix production, motility and survival [1, 2] . These translate into critical tissue functions throughout embryogenesis and adult life, achieved by striking a balance between proliferation and differentiation [2 -4] . When this balance is perturbed, the TGFb pathway malfunctions. Aberrant TGFb signalling is associated with many human diseases including immune disorders, fibrosis, cancer progression and metastasis [5] [6] [7] [8] [9] [10] [11] [12] . Therefore, understanding the molecular mechanisms underpinning the regulation of the TGFb pathway would facilitate novel therapeutic opportunities against these diseases.
TGFb signalling is initiated when ligands bind to their cognate receptors (figure 1). There are at least 42 different TGFb ligands, which are divided into two main subgroups: the TGFb family and the bone morphogenetic protein (BMP) family. Ligand binding induces specific quaternary complex formation of the transmembrane serine threonine kinase receptors. These receptors are divided into type I (ALK1-7) and type II (ACVR-IIA, ACVR-IIB, BMPR-II, AMHR-II and TGFbR-II). SMAD proteins are the intracellular transducers of the pathway; they are divided into specific subgroups: receptor-regulated (R-SMADs; 1-3, 5 and 8), the co-SMAD (4) and the inhibitory (I-) SMADs (6 and 7). Upon ligand binding, the type II receptors phosphorylate and activate the type I receptors. Activated type I receptors phosphorylate the R-SMADs at their C-terminal SXS motif. This induces R-SMAD complex formation with SMAD4 and nuclear translocation, where along with their nuclear cofactors & 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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they bind DNA and regulate transcription. The vast number of ligands and receptors allows for the formation of unique ligand-receptor complexes in distinct biological settings. In general, the TGFb receptor subfamily signals through SMADs 2 and 3, while the BMP subfamily signals through SMADs 1, 5 and 8, although some crosstalk between the two pathways has been reported. A negative feedback loop is created by TGFb-or BMP-induced transcription of the I-SMADs. I-SMADs inhibit the pathway by competing with R-SMADs for association with the type I receptors, or by recruiting E3 ubiquitin ligases and targeting the receptors for degradation. In the nucleus, a variety of nuclear cofactors are required for the R-SMADs to bind DNA and induce gene transcription (figure 1). Additionally, various histone and DNA modifiers are required for opening or closing sections of DNA to transcriptional regulation by R-SMADs [1, [13] [14] [15] [16] [17] [18] . While we focus on the role of reversible ubiquitylation in regulating the core components of the TGFb pathway in this review, they can be further regulated by multiple post-translational modifications, which also impact the outcome of TGFb signalling. Often it is the integration of all the regulatory inputs that determines the cellular responses to TGFb signals.
Reversible ubiquitylation
Ubiquitylation, also referred to as ubiquitination, is a reversible process by which ubiquitins are attached to proteins, either singly or in chains. This post-translational modification causes target proteins to undergo changes in stability, subcellular localization or activity. Ubiquitin is a member of a conserved family of small eukaryotic proteins (approx. 8.5 kDa) that share the ubiquitin fold structure. Through an isopeptide bond, ubiquitin is attached to lysine residues on the target, creating mono-ubiquitylated proteins. Attaching more ubiquitin molecules to the lysines of an already proteinbound ubiquitin creates polyubiquitin chains. Depending on which lysine the subsequent ubiquitin molecules are attached to, different fates await the polyubiquitylated proteins. While eight linkage types are possible (through K6, K11, K27, K29, K33, K48, K63 and a-amino group of ubiquitin) as well as mixed chains, not all have been attributed a function. Two linkage types are commonly studied and reported in the TGFb pathway: K48 chains are known to signal protein degradation, while K63 chains play a role in signalling as well as in protein trafficking and endocytosis.
Ubiquitin attachment is achieved through a three-step process catalysed by an E1-ubiquitin-activating enzyme, specific E2-ubiquitin-conjugating enzymes and a wide array of E3-ubiquitin ligases. E1 enzymes activate and transfer ubiquitin in an ATP-dependant manner to the E2-ubiquitinconjugating enzyme. This high-energy ubiquitin-E2 conjugate then specifically interacts with the E3-ubiquitin ligase, which could be either a single protein or part of a larger ligase complex. E3s can be divided into three structural groups, U-Box, HECT and Ring E3s, depending on their conserved domains and mode of catalysis. Several ubiquitin-like proteins (UBLs), including SUMO1-3, NEDD8, FUBI, HUB1, ISG15, FAT10, URM1, UFM1, Atg12 and Atg8, share a similar three-step attachment process. However, these UBLs use rsob.royalsocietypublishing.org Open Biol 2: 120082 different E1, E2 and E3 enzymes. While SUMO (small ubiquitinlike modifier) has been reported to modulate TGFb signalling, this review will concentrate on ubiquitin [19] [20] [21] [22] [23] [24] . The removal of ubiquitins or polyubiquitin chains from the target protein is catalysed by deubiquitylating enzymes (DUBs). Therefore, DUBs reverse the function of E3 ubiquitin ligases [25] . DUBs remove ubiquitin from cellular adducts, process inactive ubiquitin precursors, proofread ubiquitinprotein conjugates and protect the 26S proteasome from ubiquitin chain accumulation [26] . Furthermore, DUBs generate free ubiquitin by removing and chopping ubiquitin chains from proteins, leading to recycling of ubiquitin, thereby contributing to ubiquitin homeostasis. The fate of ubiquitylated proteins can be further modified by DUBs that edit or trim ubiquitin chains, resulting in a reversal of ubiquitin signalling. This could lead to protein stabilisation by rescue from degradation [25] . Deubiquitylation is implicated in several cellular functions such as gene expression, DNA repair, cell cycle regulation, kinase activation and microbial pathogenesis [27] .
DUBs are classified into five distinct functional and structural groups: the zinc metalloproteases JAMM/MPNþ, and the cysteine proteases, comprised of ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases (USPs), ovarian tumour proteases (OTUs) and Josephins [25] . There are also DUBs that resemble the adenovirus protease that cleave interferon-stimulated gene 15 (ISG15) conjugates and ubiquitin-like proteases (ULPs), which belong to the Adenain family of cysteine proteases, that are specific to ubiquitin-like proteins SUMO or NEDD8 [27] . As the human genome encodes less than 100 DUBs, it is evident that DUBs are highly regulated and play a role in diverse signalling pathways in order to oppose the action of over 600 E3 ligases [25, 28] . A combination of substrate and target choice determines overall DUB specificity, which is further regulated by conformational/post-translational changes, subcellular localization and interactions with cofactors. DUBs distinguish between ubiquitin-like molecules, isopeptides, linear peptides and different types of ubiquitin linkage and chain structures as well as exo-versus endo-deubiquitylation to ensure specificity. Enzymatic activity of DUBs is often cryptic and regulated by occluding the substrate-binding site of certain DUBs or by inducing conformational changes that activate the catalytic site. Apart from these substrate-induced conformational changes and post-translational covalent modifications, activity can also be regulated by interacting cofactors. Other events, such as transcriptional regulation of DUB expression and subcellular localization, further ensure specific ubiquitin chain cleavage. DUBs are modular and contain multiple domains that mediate protein-protein interactions, apart from their catalytic domains. These domains include ubiquitin-binding domains (UBDs) or ubiquitin-like folds (UBL folds), ubiquitininteracting motifs (UIMs), zinc finger USP domains (ZnF-UBP domain) and ubiquitin-associated domains (UBA domains). These domains contribute to the binding and recognition of different ubiquitin chain linkages but some DUBs also display direct affinity for their ubiquitylated target protein [25, 27, 28] . Recent studies have demonstrated that DUBs play critical roles in the TGFb pathway regulation [7, 29, 30] . However, the field requires further research in order to identify DUBs that regulate the TGFb pathway and understand their mode of action. Understanding the precise roles of DUBs in regulating the TGFb pathway may unravel new opportunities for therapeutic intervention.
Regulation of the TGF b pathway components by reversible ubiquitylation
The fundamental steps and the key players in the TGFb pathway are generally well defined. In this review, we focus on our understanding of how reversible ubiquitylation impacts three groups of key TGFb pathway mediators: the TGFb receptors, the SMAD transcription factors and nuclear SMAD cofactors. By integrating multiple signals, reversible ubiquitylation of these components in different biological contexts plays crucial roles in balancing the outcome of TGFb signalling. Defective ubiquitylation of the TGFb pathway components has been implicated in many human diseases, especially cancer [7,8,11,12,31 -34] .
Reversible ubiquitylation of TGF b receptors
Receptor complex assembly and activation upon binding TGFb ligands are central to the activation of intracellular signalling. The activity and integrity of type II and type I TGFb receptors can be modulated by several strategies: dephosphorylation of the activated receptors, interfering with the receptor/R-SMAD binding, changing receptor localization and/or targeting receptors for proteasomal degradation. I-SMADs play a crucial role in some of these strategies by modulating the activity and stability of active TGFb receptor complexes. SMAD7 was reported to inhibit the TGFb pathway by not only interfering with R-SMAD phosphorylation but also recruiting the E3 ubiquitin ligases SMURF1 and SMURF2 to the receptor complex (figure 2) [35, 36] . This led to both receptors (ALK5 and TGFbR-II) and SMAD7 being ubiquitylated and targeted for degradation. Similarly, SMAD6/7 has been described to direct SMURF1 to ALK6 and mediates receptor ubiquitylation and degradation [37] . Both I-SMADs and SMURF1/2 are transcriptional targets of TGFb and BMP signals, thereby creating a negative feedback loop [38, 39] . A glycosyl phosphatidylinositol-anchored protein, CD109, further enhances the SMAD7-SMURF2 receptor complex interaction, strengthening the negative feedback [40, 41] . Conversely, a recent study demonstrated that a protein named TGF-b-stimulated clone 22 (TSC-22), which is induced by TGFb, inhibits the SMAD7-SMURF complex from binding, ubiquitylating and degrading the receptor complex. As expected, this leads to enhanced TGFb signalling that translated physiologically into increased TGFb-induced cellular differentiation [42] . Tribbles homologue 3 (TRB3) is another TGFb-induced gene capable of enhancing pathway signalling in a positive feedback loop. TRB3 enhances SMAD3 nuclear localization and induces degradation of SMURF2 promoting cell migration, invasion and epithelial to mesenchymal transition (EMT) [43] . In human renal cell carcinomas, enhanced SMURF2 expression causes the reduction in levels of type II TGFb receptor by proteasomal degradation [8] . SMURF1 and SMURF2 belong to the NEDD4-like family of HECT E3 ubiquitin ligases and are characterized by the presence of a conserved C2-WW-HECT domain structure [44] . While the C2 domain regulates the subcellular localization, the WW domains are 38-40 residue rsob.royalsocietypublishing.org Open Biol 2: 120082 motifs characterized by two highly conserved tryptophans and folded as a three-strand b sheet that associate with the prolinerich 'PPXY' motif (also known as 'PY' motif) [45] . The PY motif present in the linker region of SMAD7 interacts with one of the WW domains of SMURF1/2 [35] . Other members of the NEDD4-like family, WWP1 and NEDD4L, have also been shown to interact with SMAD7 and target ALK5 for ubiquitylation and degradation. However, unlike SMURF1/2, they did not target SMAD7 itself for ubiquitin-mediated degradation, possibly providing a stronger and longer lasting negative regulation of the pathway [46] [47] [48] . In our studies, we have identified three further members of the NEDD4-like family of E3s, namely NEDD4, WWP2 and ITCH, as SMAD6/7 interactors. These are also likely to act in a similar mode to regulate the activity and stability of the TGFb receptors. The precise nature of ubiquitin attachment and the sites for ubiquitylation on TGFb receptors remain undefined. While several E3s have been implicated to act on the TGFb receptors, to date very few E2-ubiquitin-conjugating enzymes have been assigned. SMAD7 has been reported to facilitate the recruitment of UbcH7, an E2 enzyme, to SMURF2 thereby providing a pathway-specific control on SMURF2 activity [49] . The regulation of TGFb receptors by DUBs would be predicted to reverse the effects of E3 ubiquitin ligases and positively regulate the TGFb pathway. To date, only two studies have addressed deubiquitylation of the receptors. UCH37 was reported to target ALK5 for deubiquitylation thereby enhancing TGFb signalling [50] . However, structural studies on the UCH family of DUBs imply they are di-or polyubiquitin chain editors [25] . USP15 was identified as a modulator of TGFb-induced transcription from a pan DUBsiRNA screen and subsequently shown to act on ALK5. The study further linked USP15 gene amplification with poor prognosis in glioblastoma [7] . 
The BMP pathway SMADS
The first E3 ligase reported to ubiquitylate BMP-responsive SMADs was SMURF1 [51] . The WW domain of SMURF1 interacts with the PY motif of SMAD1/5 and targets them for ubiquitylation and proteasomal degradation [51, 52] . Studies in Xenopus embryos showed that SMURF1 causes dorsalization of ventral mesoderm and neuralization of ectoderm, phenotypes consistent with inhibition of the BMP pathway [51] . SMURF1-mediated SMAD1/5 ubiquitylation promotes myogenic differentiation of C2C12 cells, blocks BMP-2-mediated osteogenic conversion [52] and modulates the effects of BMP4 on embryonic lung growth [53] . In contrast, SMURF1 has been shown to have little effect on TGFb-inhibited myogenic differentiation [51, 52] . LMP-1, an LIM domain protein capable of inducing de novo bone formation that contains a WW domain, interacts with SMURF1 and competes with SMAD1/5 for binding . Consequently, LMP-1 prevents SMURF1-mediated SMAD1/5 ubiquitylation and results in increased cellular responsiveness to BMP signals [54] . The PY motif in SMAD1/5 is preceded by a cluster of Ser/Thr residues. Phosphorylation of these residues, catalysed by proline-directed Ser/Thr protein kinases (e.g. MAP kinases and CDK8/9), in response to different stimuli as well as glycogen synthase kinase-3 (GSK-3) is essential for its interaction with SMURF1 [55 -57] . BMP-induced sequential linker phosphorylation of SMAD1 by CDK8/9 and GSK-3 primes SMAD1 for transcriptional action and degradation, respectively. While phosphorylation by CDK8/9 induces recruitment of YAP1 mediator through its WW domain, subsequent phosphorylation by GSK-3 displaces YAP1 and recruits SMURF1 [45, 55] . YAP1 stability is further regulated by SCF (Skp, Cullin, F-box)-bTRCP-induced ubiquitylation [58] . These studies demonstrate a clear interplay between phosphorylation and ubiquitylation in balancing the outcome of BMP pathway rsob.royalsocietypublishing.org Open Biol 2: 120082
signalling. SMURF2 has also been shown to polyubiquitylate SMAD1 and mediates its degradation. Studies in Xenopus embryos confirmed that SMURF2 inhibits SMAD1 responses [59, 60] . SMAD8 lacks the PY motif in its linker region and would be predicted to be resistant to SMURF-mediated ubiquitylation and degradation. A U-box-dependent E3 ubiquitin ligase member carboxyl terminus of Hsc70-interacting protein (CHIP) was reported as an interactor of SMAD1. CHIP was shown to cause ubiquitylation and degradation of SMAD1, resulting in the inhibition of the BMP-induced transcriptional activity [61] . The lysine residues within BMP-SMADs modified by ubiquitylation, the nature of polyubiquitin linkages and the E2-ubiquitin-conjugating enzymes involved remain to be defined. No DUBs for BMP-SMADs have been reported.
The TGF b pathway SMADs
Among the SMADs, TGFb-SMAD ubiquitylation has received the most scrutiny. The evidence for polyubiquitylation and degradation of TGFb-induced phospho-SMAD2 was first demonstrated in 1999 [62] . Subsequently, several E3 ubiquitin ligases, including SMURF1/2, NEDD4L and WWP1, have been implicated in mediating the polyubiquitylation and degradation of SMAD2/3 [47, 48, 59, 63] . These NEDD4-like E3 ubiquitin ligase members all use the PY motif present in the SMAD2/3-linker for interaction. However, the recruitment of NEDD4L to SMAD2/3 requires the phosphorylation of the linker region mediated by CDK8/9 as well as the PY motif [64] . A WW-domain-containing protein PIN1 has been implicated in recruiting SMURF2 to linker-phosphorylated SMADs [65] . NEDD4L itself is also subject to further regulation by serum/glucocorticoid-regulated kinase 1 (SGK1), which is itself a transcriptional target of TGFb signalling [64] . Signal termination is also achieved by other E3 ligases, independent of linker phosphorylation, using SMAD2/3 interactions with transcriptional cofactors. The ROC1-SCF-bTRCP RING E3 ligase complex targets activated SMAD3 for nuclear export and ubiquitin-mediated degradation upon its association with the transcriptional co-activator p300 [66] . The transcriptional regulator TAZ, reported to be required for SMAD2/3/ 4 complex nuclear accumulation, is also regulated by SCFbTRCP-induced ubiquitylation and degradation [67, 68] . While the previous examples show SMAD2/3 regulation after TGFb signal initiation, CHIP has been shown to interact with ubiquitylate and degrade basal SMAD3 levels, resulting in the inhibition of TGFb signalling [69] . SMURF2 features prominently in reports describing SMAD2/3 degradation. SMURF2-mediated inhibition of TGFb signalling has been demonstrated across multiple organisms and in obstructive nephropathy [34, 39, 65, 70] . One area of contention is whether SMURF2 polyubiquitylates [39, 65, 70] or monoubiquitylates [34] the TGFb SMADs, targeting them for degradation or inhibiting complex formation with SMAD4, respectively. Nonetheless, both outcomes are reported to result in TGFb signalling inhibition.
A member of the RING E3 ubiquitin ligase family, ARKA-DIA, was initially reported to ubiquitylate phosphorylated SMAD2/3 in the nucleus [71] . Despite this, ARKADIA resulted in enhanced TGFb signalling. While counterintuitive, this was consistent with previous reports showing the effect of ARKADIA on Nodal signalling [72, 73] . It was later shown that ARKADIA targets the inactive phospho-SMAD2/3-SKI complex for ubiquitylation and degradation rsob.royalsocietypublishing.org Open Biol 2: 120082 [74] . SKI is a nuclear cofactor that negatively regulates TGFb signalling by binding phosphorylated SMADs and preventing their transcriptional activity. ARKADIA balances SKI and SMAD2/3 ubiquitin-mediated degradation enhancing pathway transcriptional responses while terminating signalling once that is achieved. Changing the balance leads to TGFb-pathway-related pathology in colorectal cancer where mutations leading to a reduction in ARKADIA function have been reported [11] . WWP1/2 have also been implicated in ubiquitylation and destabilization of SMAD2/3 [48, 75] . While ITCH and CBLB E3 ubiquitin ligases have been reported to ubiquitylate SMAD2, they promote TGFb-induced SMAD2 phosphorylation and signalling [76] [77] [78] . Although ITCH mediates the attachment of K48-linked ubiquitin chains on SMAD2, no degradation is observed [77] . This indicates that certain K48-linked polyubiquitin chains may have functions beyond proteasome-mediated degradation. Despite numerous E3 ubiquitin ligases proposed to ubiquitylate the TGFb SMADs, USP15 is the only deubiquitylase reported to act on SMAD2/3 [30] . USP15 has been reported to reverse SMAD2/3 monoubiquitylation, which targets the DNA-binding domains of SMAD2/3 and inhibits promoter recognition. The DUBs reversing the polyubiquitylation of SMAD2/3 remain to be defined.
SMAD4
Association of SMAD4 with R-SMADs is a critical step in the canonical TGFb and BMP signalling pathways. Preventing this association or targeting SMAD4 for degradation inhibits TGFb/BMP signalling. Regulation of SMAD4 by both monoand polyubiquitylation has been reported [61, [79] [80] [81] [82] [83] [84] . Despite the lack of an intact PY motif, SMAD4 is polyubiquitylated by SMURF1/2, WWP1 and NEDD4L, which are recruited to SMAD4 by their association with I-SMADs and SMAD2 [83] . The E3 ligase CHIP has been implicated in controlling SMAD4 stability; however its role in SMAD4 ubiquitylation is unclear [61] . SCF complexes have been reported to ubiquitylate and degrade SMAD4. b-TRCP1 was initially shown to bind SMAD4 and induce its ubiquitin-mediated degradation through SCF. In the absence of SMAD4, the over-expressed complex was unable to inhibit TGFb-induced cell cycle arrest [84] . SCF -bTRCP1 complex has been reported to control SMAD4 stability in pancreatic cancer cells [12] . The other SCF complex with SKP2 was also shown to bind and degrade SMAD4 [82] . Interestingly, TGFb induces destruction of SKP2 in the nucleus, providing a further layer of control in the feedback loop [81] .
The RING E3 ubiquitin ligase TRIM33 (also known as Ectodermin/TIF1g), which also contains a plant homeodomain (PHD)-Bromo domain, has been proposed to interact with and ubiquitylate SMAD4 [80] . Although the critical role of TRIM33 on the TGFb pathway is not debated, reports on the mechanisms by which it achieves this differ greatly. Two modes of action have been proposed. (i) TRIM33 interacts with phosphorylated SMAD2/3 in competition with SMAD4, thereby interfering with SMAD2/3-SMAD4 binding and creating separate SMAD2/3-SMAD4 and SMAD2/3-TRIM33 complexes, each resulting in distinct functions on cellular processes [85, 86] . Furthermore, the PHD-Bromo domain has been demonstrated to be essential for the recruitment of TRIM33 to chromatin [79, 86] . (ii) TRIM33 directly interacts with SMAD4
and not SMAD2/3, catalyses its polyubiquitylation [80] or mono-ubiquitylation at Lys519, which inhibits SMAD2/3-SMAD4 complex formation [29] . It has been shown that chromatin binding is required for the E3 ligase activity of TRIM33 in vitro [79] . While targeted disruption of the TRIM33 gene in mice has established the role for TRIM33 in limiting Nodal responsiveness in vivo [87] , it has not resolved the debate on its mode of action. A mouse or a cell-line model in which wild-type TRIM33 is replaced by a catalytically inactive mutant with an intact PHD-Bromo domain would resolve definitively the issue of whether the E3 ligase activity of TRIM33 on SMAD4 is necessary for its influence on the TGFb pathway.
USP9X/FAM is the only deubiquitylase reported to reverse the monoubiquitylation of SMAD4 at Lys519 mediated by TRIM33 [29] . Depletion of USP9X resulted in inhibition of TGFb-induced transcriptional and cellular responses but not phospho-SMAD3. USP9X interacted with and deubiquitylated SMAD4 [29] .
Inhibitory SMADs 6/7
In the light of multiple reports on the inhibitory effects of I-SMADs, inducing I-SMAD polyubiquitylation and degradation would be predicted to strongly enhance TGFb/BMP pathway signalling. Although SMAD6/7 interact with the majority of NEDD4-like E3 ubiquitin ligases through their PY motif, these E3s primarily employ SMAD7 as an adaptor to target various substrates, including the TGFb/BMP receptors. In the process, I-SMADs are often destroyed by proteasomal degradation [35, 36] . ARKADIA, an E3 ligase that does not target the receptor complex, has been shown to target SMAD7 for ubiquitylation and degradation, thereby enhancing pathway signalling [88, 89] . ARKADIA also targets multiple components of the TGFb pathway for ubiquitylation and degradation [11, 65, 71, 74, [90] [91] [92] [93] . However, selective SMAD7 polyubiquitylation and degradation has been reported in renal fibrosis and hypertension mouse models, causing enhanced pathway signalling [31, 94] .
Inhibition of I-SMAD ubiquitylation and subsequent degradation would provide a clear way to negatively control the TGFb pathway. The histone acetyl transferase, p300, has been reported to acetylate SMAD7 at Lys64 and Lys70, the same residues in which ubiquitylation occurs. This prevents SMAD7 from being targeted by E3s for ubiquitylation and degradation [95, 96] . It has also been reported that the de-acetylase SIRT1 can reverse this, creating an acetylation/ de-acetylation balance controlling SMAD7 fate [97, 98] .
The only DUB reported to target the I-SMADs is CYLD [99] . The study performed in CYLD-knockout mice reported that CYLD targets SMAD7 protein for deubiquitylation and inhibits TGF-b signalling in the development of regulatory T cells. Moreover, CYLD appears to deubiquitylate SMAD7 at Lys360 and Lys374 but not at Lys64 or Lys70 [99] .
Regulation of nuclear SMAD cofactors by reversible ubiquitylation
Once the activated R-SMAD -SMAD4 complex is translocated into the nucleus, it must then bind promoter sequences to positively or negatively regulate the expression of TGFb response genes. However, SMAD proteins on their own rsob.royalsocietypublishing.org Open Biol 2: 120082
have low DNA-binding affinity and require other cofactors for DNA binding [16] . Additionally, as previously described, some nuclear adaptor proteins actually inhibit SMAD -DNA binding, thereby negatively regulating SMAD transcriptional activity. Therefore, reversible ubiquitylation of nuclear cofactors can modulate TGFb-induced transcriptional activity. RUNX2 is a transcription factor that promotes R-SMAD/ DNA binding in the BMP pathway. SMURF1 has been reported to induce its ubiquitylation and degradation [100] . SMURF1 is recruited to RUNX2 by its association with SMAD6 [101] . Most other reports have concentrated on the regulation of negative nuclear cofactors SKI and SnoN that antagonize SMAD-mediated transcriptional activity. TGFbinduced SMURF2/SMAD2 binding and targeting of SnoN release the negative regulation of SnoN on nuclear SMAD transcriptional activity in both physiological and pathological pathway signalling [33, 102] . ARKADIA is reported to target both SKI and SnoN for ubiquitin-mediated degradation in a similar TGFb-dependent fashion, leading to activation of transcriptional responses [91, 92] . Later reports also identify that SKI ubiquitylation and degradation requires TGFb signalling and ARKADIA binding to phosphorylated-SMAD2/3 [74, 93] . ARKADIA function is itself regulated by binding to proteins such as AXIN and RB1CC1 [89, 90] . The anaphase-promoting complex E3 ligase has also been reported to act in a similar manner by targeting SnoN [103, 104] , while the CDC34 E2 targets SKI and SnoN in a cell-cycle-dependent fashion [105] . Very little is known about the DUBs that reverse the ubiquitylation of the earlier-mentioned nuclear SMAD cofactors.
Concluding remarks
The (table 1) . While many candidate E3 ubiquitin ligases have been proposed, little is known about the E2-ubiquitin-conjugating enzymes further upstream. Several members of the NEDD4-like family of E3 ubiquitin ligases have been reported to catalyse the polyubiquitylation and degradation of both TGFb receptors and SMAD transcription factors. Indeed, SMURF1/2 appears to be transcriptional targets of TGFb cytokines themselves and inhibit the pathway through a negative feedback loop [18] . The observations that the recognition of SMAD1 and SMAD2/3, by SMURF1 and NEDD4L, respectively, requires phosphorylation of linker regions of SMAD proteins imply an active interplay between phosphorylation and ubiquitylation processes [57, 64] . Such crosstalk is likely to happen across [106] . While functional redundancy between SMURF1 and SMURF2 may have contributed to the lack of striking phenotypes in SMURF1-or SMURF2-knockout mice, double knockout resulted in embryonic lethality with severe defects in planar cell polarity [34, 106, 107] . As most E3 ubiquitin ligases implicated in the TGFb pathway are likely to have several substrates, observed phenotypes could be attributed to effects on their most critical targets, thereby confusing any impact relating to the TGFb pathway. Pathway-specific E3 mutants would therefore be required for such physiological studies relating to one pathway over any others targeted by E3 ligases. Understanding the molecular mechanisms by which the E3 ubiquitin ligases recognize specific substrates, and how they are activated, would be essential to producing such pathway-specific physiological mouse models. The precise mechanisms by which all reported E3 ubiquitin ligases are activated or recognize their substrates in the TGFb pathway are still not well defined.
Deciphering the mechanisms of how TGFb receptor kinases mediate the phosphorylation of R-SMADs has resulted in our understanding of the fundamental aspects of TGFb signalling [1] . The precise ubiquitylation sites within receptors, SMAD proteins or SMAD cofactors as well as the nature of polyubiquitin chains that are attached to the initial ubiquitin are largely undefined. Most of the ubiquitylation sites reported on SMAD proteins thus far have resulted from over-expression and mutagenesis studies, which have the potential of yielding artefacts. Recent technologies capable of identifying ubiquitylated peptides on endogenous proteins hold great promise for investigating reversible ubiquitylation in the TGFb pathway [108, 109] . Indeed one of these studies was able to identify multiple ubiquitylation sites within endogenous type I TGFb/BMP receptors as well as BMP and TGFb ligands. That the ligands could themselves be regulated by ubiquitylation is an intriguing observation that has as yet eluded consideration entirely.
Investigation into the regulation of the TGFb pathway by DUBs is an emerging research field. To date, only three DUBs, namely UCH37, USP9X and USP15, have been attributed a role in deubiquitylating components of the TGFb pathway (table 1) [7, 29, 30, 50] . The mode of substrate recognition and catalysis of reported TGFb pathway DUBs are still undefined. Because of their limited number in the genome, DUBs are likely to be promiscuous with regard to their substrate range. Therefore, RNAi-based global DUB knockdown strategies employed to identify TGFb pathway regulators have to be used cautiously. A better strategy would be to identify DUBs that associate directly with specific TGFb pathway components. Understanding the molecular mechanisms by which DUBs recognize their substrates is critical in defining their roles on specific targets. In addition to being peptidases, the DUBs possess a characteristic in being able to recognize and bind to uniquely ubiquitylated proteins or ubiquitin chains. This ability alone, regardless of their catalytic activity, may serve an important regulatory purpose during signalling by modulating the activity, subcellular localization or stability of the target protein. Indeed, recent reports demonstrate that DUBs influence protein function independently of their deubiquitylating activity. As an example, USP7 was demonstrated to increase the binding affinity of p53 to its target genes independent of its deubiquitylase activity [110] . Similar analogies may hold true for DUBs in the TGFb pathway.
The TGFb pathway components are frequently compromised in numerous diseases, including fibrosis, cancer progression and metastasis [7, 8, 11, 12, [31] [32] [33] [34] 94] . Therefore, understanding the molecular mechanisms by which reversible ubiquitylation regulates TGFb signalling may hold some therapeutic promise against these diseases. Amplification of several members of the NEDD4-like E3 ligases, including SMURF1/2, is reported to be associated with tumour progression [44] . Reduced ARKADIA activity is associated with the pathogenesis of colorectal cancers [11] . The efficacy of the proteasome inhibitor Bortezomib against B cell lymphoma demonstrates that ubiquitin ligases and the ubiquitylation system could be exploited as targets for anti-cancer therapies [111] . DUBs, which constitute the largest family of peptidases, are also associated with many human diseases, including cancer and could make attractive therapeutic targets [7, 111, 112] . Therefore, targeting the TGFb-pathway-specific E2-ubiquitin-conjugating enzymes, E3-ubiquitin ligases or DUBs for inhibition may provide opportunities for the development of therapies against diseases in which the TGFb pathway is compromised.
